CClinicalTrials.gg
Not yet recruitingNCT06408428MicroECoGGUpdated Mar 12, 2025

Glioma Intraoperative MicroElectroCorticoGraphy

An interventional study of PANAXIUM MicroECoG in Glioma and Epilepsy, sponsored by Institut National de la Santé Et de la Recherche Médicale, France. Not yet recruiting at 3 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-12.

Sponsored by Institut National de la Santé Et de la Recherche Médicale, France · Not applicable, Interventional, and Device feasibility

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to validate the safety and to assess the quality of the signals provided by newly developed micro ElectroCorticoGraphy electrodes, provided by the company Panaxium, based on conductive polymers (PEDOT:PSS) in patients suffering of gliomas during resection surgery performed in awake condition. The main questions it aims to answer are:

  • Safety of PEDOT:PSS microECoGs by assessing the rate of serious adverse events associated with their use during glioma surgery.
  • Quality of PEDOT:PSS microECoGs recordings, as compared with recordings with traditional macroelectrodes, assessed by signal-to-noise ratio, impedance, ability to detect ripples (100-250 Hz) and fast ripples (250-600 Hz), ability to record epileptic activity (spikes and equivalent) either spontaneously or following direct electrical stimulation (afterdischarges).
  • Practicality of microelectrodes use as perceived by neurosurgeons.
  • Exploratory objectives: ability to record multi-unit activity, correlation between microECoG activity and tumor infiltration - local oncometabolite concentrations, determination of epileptic seizure rate during electrode use.

Participants will be recorded during awake glioma surgery by the newly developed micro ElectroCorticoGraphy electrodes and by routine macroelectrodes, as standard of care during both mapping of cortical activities and electrical stimulations used to assess the functional mapping mandatory for tailored tumor resection.

Read the detailed description

Electroencephalography (EEG) is a widely-used tool for studying brain activity, developed in humans in the late 1920s. Its indications have evolved as brain imaging techniques have developed, but it remains extremely useful in the fields of epileptology, comas, brain death, post-anoxic, metabolic, toxic encephalopathies and encephalitis. Alongside scalp EEG, intracranial recordings have been developed to optimize the localization of epileptic activity, with a view to epilepsy surgery.

Two main categories of intracranial electrodes are currently in use.

  1. StereoElectroEncephalopGraphy electrodes consist of a stylus with a string of cylindrical contacts along its length, implanted directly into the brain parenchyma.
  2. ElectroCorticoGraphy (ECoG) electrodes, non-penetrating, organized in strips or grids of 4 to 64 electrodes, disc-shaped, 0.2 to 1 cm in diameter, 0.5 to 1 mm thick, used to collect cerebral activity at the cortical surface.

Among its indication, surgery is a favorable circumstance for using ECoG. During brain surgery, cortical exposure enables cortical EEG recording without additional invasiveness. Intraoperative ECoG is of particular interest in epilepsy surgery, recently reactivated by the discovery of better electrophysiological biomarkers. In glioma surgery, often performed under awake conditions, cortical recording helps to establish a functional cerebral map and to adapt the resection. Indeed, ECoG recordings can be performed during awake surgery, without any disturbance of neuronal activity by anesthesia, to map epileptic activity (using visual identification of spikes) and to look for seizures induced by electrical stimulation. The evolution of these recording techniques is moving towards the development of tools for automatic analysis and mapping of new biomarkers, more relevant but more difficult to record because they are more focal and characterized by amplitudes close to background noise, such as high-frequency oscillations. New types of cortical electrodes are being developed to improve the spatial resolution (better localization), temporal resolution (faster activity detection) and detection sensitivity (signal-to-noise ratio) of cortical electrical signals.

New electrodes have recently been developed, based on the use of conductive organic polymer coatings such as poly(3,4-ethylenedioxythiophene (PEDOT: PSS), to optimize the signal-to-noise ratio, organized in electrode arrays that are 100 times thinner (5 microns vs. 0.5 mm for standard electrodes), 250 times smaller (between 30 and 500 microns vs. 8 mm for standard electrodes) and with more electrodes (128 vs. 6 or 8 for standard electrodes). This type of electrode, known as microECoG, has been validated in animals and has already been used in human research for intraoperative cortical recordings. They enable us to improve the quality of the recorded signal and to go down to a new scale, at the level of the neuron. Moreover, the very low thickness of the electrodes improves their conformability to the cortex, making them much more tolerable and enabling extended recordings to be envisaged as part of future man/machine interfaces.

The French company Panaxium is developing microECoG electrodes. As part of a collaborative project, Panaxium have designed a 4x2 cm, 6 micron-thick electrode comprising 128 electrodes (28 500 µm electrodes, 96 30 µm diameter microelectrodes organized as tetrodes and 4 reference electrodes) for clinical use in humans. The aim of this study is to explore the safety and quality of signals collected by the Panaxium microECoG during awake surgery for brain gliomas. Recording will be carried out using a high-performance EEG system CE-marked for medical use in humans.

The electrode will be placed on the cortical surface and repositioned every 90 seconds to sample the entire exposed brain surface. During the cortical electrical stimulation mapping phase, the electrode will be left at the edge of the field to detect epileptic discharges induced by stimulation. After resection, a new recording of the residual cortical surface will be made to check for persistent electrical anomalies. The surgeries and recordings will be carried out in 3 centers by neurosurgeons with expertise in brain tumors and awake surgery: Hôpital Sainte-Anne/GHU Paris), Hôpital Pietié-Salpêtrière, Hopital Fondation Adolphe de Rostschild. In the last 10 patients, the Panaxium microECoG will be compared with a macro-electrode for clinical use.

The primary endpoint will be the incidence of Serious Adverse Events due to the use of Panaxium microelectrodes during surgery and the following four days: cortical lesion by the electrode, infection, bleeding, aseptic meningitis, neurological deficit due to the use of the electrode, death. Secondary evaluation criteria will be the quality of recordings enabled by the Panaxium microECoG (signal-to-noise ratio reflecting signal quality, electrode impedance during surgery reflecting technical quality, detection of fast ripple (100-250 Hz) and fast ripple (250-600 Hz) oscillations), only possible with high-performance recorders, ability to record spontaneous epileptic activity (spikes and equivalent) or direct post-electrical stimulation (post-discharges)) and practicality of use as perceived by neurosurgeons. Finally, as an exploratory study for future uses of these electrodes, we will investigate their ability to record multi-unit activity (action potentials from single neurons) and the correlation between recorded activity and tumor infiltration, as well as local oncometabolite concentration.

02

Conditions studied

  • Glioma
  • Epilepsy

Browse trials for

Keywords

  • Glioma surgery
  • Awake surgery
  • MicroElectroCorticoGraphy
  • EEG
03

In context

Glioma

1,397 studies on the registry are indexed under Glioma; 351 are open to participants now.

This study's planned enrollment of 50 is above the median of 32 across 1,065 interventional studies indexed under Glioma.

Browse Glioma studies →

Lead sponsor

Institut National de la Santé Et de la Recherche Médicale, France is the lead sponsor of 375 studies on the registry; 82 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients suffering of a diffuse cerebral glioma for which surgical resection is indicated.
  • Planned awake surgery with intraoperative functional mapping.
  • Planned surgery with ECoG electrophysiological monitoring.
  • Age greater than or equal to 18 years.
  • Enrolled in a social security scheme, Couverture Médicale Universelle (CMU) or equivalent.
  • Have given written consent.

Exclusion criteria

Exclusion Criteria:

  • Acute or untreated infection (viral, bacterial or fungal).
  • Current treatment with antibiotics.
  • Pregnant or breast-feeding women.
  • Other pathologies that could interfere with the neurological evaluation or compromise the subject's safety.
  • Participation in therapeutic biomedical research that could modify the lesion or its environment during the study period (whether by drug or medical device) or subject to an exclusion period for other research.
  • Adult subject to legal protection
05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Glioma Surgery - MicroECoG recording

    Device: PANAXIUM MicroECoG

Interventions

  • DevicePANAXIUM MicroECoG

    The PANAXIUM microelectrode ( 4x2 cm, 6 micron-thick electrode comprising 128 electrodes (28 500 µm electrodes, 96 30 µm diameter microelectrodes organized as tetrodes and 4 reference electrodes) will be placed on the cortical surface and repositioned every 90 seconds to sample the entire exposed brain surface. During the cortical electrical stimulation mapping phase, the electrode will be left at the edge of the field to detect epileptic discharges induced by stimulation. After resection, a new recording of the residual cortical surface will be made to check for persistent electrical anomalies. In the last 10 patients, the Panaxium microECoG will be compared with a macro-electrode for clinical use.

06

What researchers measure

Primary outcomes

  1. Safety of PEDOT:PSS microECoGs use

    Assessment of the safety of PEDOT:PSS microECoGs use by assessing the rate of serious adverse events associated with their use during glioma surgery

    Time frame: 30 months

Secondary outcomes

  1. Quality of PEDOT:PSS microECoGs recordings

    Quality of PEDOT:PSS microECoGs recordings assessment by signal-to-noise ratio, impedance, ability to detect ripples (100-250 Hz) and fast ripples (250-600 Hz), ability to record epileptic activity (spikes and equivalent) either spontaneously or following direct electrical stimulation (afterdischarges)

    Time frame: 30 months

  2. Practicality of microelectrodes use as perceived by neurosurgeons.

    Practicality of microelectrodes use as perceived by neurosurgeons.

    Time frame: 30 months

Other outcomes

  1. ability to record multi-unit activity, correlation between microECoG activity and tumor infiltration - local oncometabolite concentrations, determination of epileptic seizure rate during electrode use

    ability to record multi-unit activity, correlation between microECoG activity and tumor infiltration - local oncometabolite concentrations, determination of epileptic seizure rate during electrode use

    Time frame: 30 months

07

Study locations

3 sites
  • Hôpital Pitié Salpêtrière
    Paris, 75013, France
    • Bertrand MATHON, PhD · Contact
    • Bertrand MATHON, PhD · Principal investigator
  • Centre Hospitalier Sainte-Anne
    Paris, 75014, France
  • Hôpital Fondation Adolphe de Rothschild
    Paris, 75019, France
    • Gilles HUBERFELD, PhD · Contact · ghuberfeld@for.paris
    • Gilles HUBERFELD, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06408428
Lead sponsor
Institut National de la Santé Et de la Recherche Médicale, France
Collaborators
PANAXIUM
Responsible party
Sponsor
First posted
May 10, 2024
Start date
Sep 2025 (estimated)
Primary completion
Sep 2027 (estimated)
Completion
Mar 2028 (estimated)
Last update
Mar 12, 2025

Study contacts

Gilles Huberfeld, MD, PhD
Contact
gilles.huberfeld@inserm.fr
+331 40 78 92 87
Gilles Huberfeld, MD, PhD
principal investigator · Institut National de la Santé Et de la Recherche Médicale, France

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion